CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

May 28 (Reuters) - CVS Health will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional ...

More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after ...

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...

Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would ...

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates, as demand for its blockbuster ...

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or ...

Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit.

Eli Lilly's fundamentals matter more than Trump's stock purchases.